Bromophenolred (BPR) is a chemical indicator. It has been shown to bind to lysozymes and inhibits their activity against bacterial cell walls, but not against the polysaccharide component of peptidoglycan.
Ambroxol-d5 is intended for use as an internal standard for the quantification of ambroxol by GC- or LC-MS. Ambroxol is an expectorant and active metabolite of bromhexine. It decreases short-circuit currents in electrically stimulated isolated canine tracheal epithelial cells when applied submucosally. Ambroxol decreases IL-13-induced production of mucin 5AC (MUC5AC) in primary human airway epithelial cells and inhibits IL-13-induced decreases in the mucociliary transport rate of endogenous particles in the same cells. Ambroxol increases phenolred secretion, a marker of expectorant activity, in mice when administered at doses of 30, 60, or 120 mg kg. Formulations containing ambroxol have been used in the treatment of acute or chronic respiratory conditions.
Guaifenesin-d3 is intended for use as an internal standard for the quantification of guaifenesin by GC- or LC-MS. Guaifenesin is an expectorant. It inhibits production of mucin 5AC (MUC5AC), reduces mucus viscosity and elasticity, and increases the mucociliary transport rate of endogenous particles in primary human tracheobronchial epithelial cells in a concentration-dependent manner. Guaifenesin increases phenolred secretion, a marker of expectorant activity, in rats.3 Formulations containing guaifenesin have been used as expectorants in the treatment of the common cold and chronic bronchitis.